Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial

British Journal of Cancer

Volumn 96, Issue 11, 2007, Pages 1633-1638

  Kerbrat, P ^a   Roche H ^b   Bonneterre, J ^c   Veyret, C ^d   Lortholary, A ^e   Monnier, A ^f   Fumoleau, P ^g   Fargeot, P ^h   Namer, M ⁱ   Chollet, P ^j   Goudier, M J ^k   Audhuy, B ^l   Simon, H ^m   Montcuquet, P ⁿ   Eymard, J C ^o   Walter, S ^p   Clavere P ^q   Guastalla, J P ^r  

^a UNIVERSITÉ DE RENNES 1   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d CENTRE HENRI BECQUEREL   (France)

^e CENTRE PAUL PAPIN   (France)

^f Centre Hospitalier General Andre Boulloche   (France)

^g CENTRE RENÉ GAUDUCHEAU   (France)

^h CENTRE GEORGES FRANÇOIS LECLERC   (France)

ⁱ CENTRE ANTOINE LACASSAGNE   (France)

^j CENTRE JEAN PERRIN   (France)

^k Centre Hospitalier de Bretagne Sud   (France)

^l Pasteur Hospital   (France)

^m BREST UNIVERSITY HOSPITAL   (France)

ⁿ CliniqueSaint Vincent ^*  (France)

^o INSTITUT JEAN GODINOT   (France)

^p Bon Secours Hospital   (France)

^q DUPUYTREN UNIVERSITY HOSPITAL   (France)

^r CENTRE LÉON BÉRARD   (France)

more..

Author keywords

Adjuvant chemotherapy; Early breast cancer; Epirubicin; Vinorelbine

Indexed keywords

ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; NAVELBINE; TAMOXIFEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOKALEMIA; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; FLUOROURACIL; FRANCE; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 34249815226     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603773     Document Type: Article

References (22)

1. Blajman C, Balbiani L, Block J, Coppola F, Chacon R, Fein L, Bonicatto S, Alvarez A, Schmilovich A, Delgado FM (1999) A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer 85: 1091-1097
2. Bonneterre J, Roche H, Kerbrat P, Bremond A, Fumoleau P, Namer M, Goudier MJ, Schraub S, Fargeot P, Chapelle-Marcillac I (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23: 2686-2693
3. Canobbio L, Boccardo F, Pastorino G, Brema F, Martini C, Resasco M, Santi L (1989) Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 16(Suppl 4): 33-36
4. Crown JP, Francis P, Di Leo A, Buyse M, Balil A, Anderson M, Nordenskjöld B, Jakesz R, Gutierrez J, Piccart M (2006) Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2-98 Trial at 5 years median follow-up (MFU). Proc Am Soc Clin Oncol 25, Abstract LBA519
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
7. French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19: 602-611
8. French Epirubicin Study Group (1988) A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 6: 679-688
9. Fumoleau P, Bonneterre J, Luporsi E (2003) Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today? J Clin Oncol 21: 1190-1192
10. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245-1252
11. Fumoleau P, Roche H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier MJ, Luporsi E (2006) Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results. Ann Oncol 17: 85-92
12. García-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, De Pablo JL, Gorostiaga J, Giron GC, Cervantes A, Martínez A, Pezous N, Delgado FM, Díaz Rubio E (1994) Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5: 854-857
13. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei III E, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976-983
14. Italian Multicentre Breast Study with Epirubicin (1988) Phase III randomised study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian Mulitcentre Trial. J Clin Oncol 6: 976-982
15. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354: 809-820
16. Kerbrat P, Roché H, Bonneterre J, Bastit P, Lortholary A, Monnier A, Fargeot P, Namer M, Chapelle-Marcillac I (2002) Can we substitute an epirubicin- vinorelbine regimen to 6 cycles of FEC 100 (FEC100) as adjuvant chemotherapy of operable, node-positive (N+) breast cancer (BC) patients (pts): 5-year follow-up results of FASG-09. Proc Am Soc Clin Oncol 21, Abstract 189, p48a
17. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23: 3686-3696
18. Mouridsen HT (1990) New cytotoxic drugs in treatment of breast cancer. Acta Oncol 29: 343-347
19. Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Kerbrat P, Serin D, Lortholary A, de Ghislain C, Viens P, Bergerat JP, Genève J, Martin AL, Asselain B (2004) Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer 27th San Antonio Breast Cancer Symposium; 8-11 December 2004 San Antonio, TX, Abstract 27
20. Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rouesse J, Pouillart P, Tursz T (1994) Phase II trial of vinorelbine/ doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12: 1764-1770
21. Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA, Brown Jr BW, Hannigan Jr JF, Meyers FJ, Mitchell EP (1986) Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46: 3722-3727
22. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13: 2722-2730